Accelerated Approval – Expedited Program for Serious Conditions
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 5, 2024
December 5, 2024
7bda38cb-af37-463c-93d1-9a573a6f6fc9
Related Documents
Drug Master Files Guidance for Industry
Guidance DocumentNovember 15, 2019Center for Drug Evaluation and Research
Considerations for Rescinding Breakthrough Therapy Designation
Guidance DocumentJune 24, 2022Center for Drug Evaluation and Research
Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products
Guidance DocumentSeptember 8, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.